Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
复制标题
SARS-CoV-2抗体的两种不同的抗体依赖性增强（ADE）风险。
DOI：
10.3389/fimmu.2021.640093
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Ricke DO
中科院分区：
文献类型：
--
作者：
Ricke DO
COVID-19 (SARS-CoV-2) 疾病的严重程度和阶段各不相同，包括无症状、轻度流感样症状、中度、重度、危重和慢性疾病。 COVID-19疾病进展包括淋巴细胞减少、促炎细胞因子和趋化因子升高、肺部巨噬细胞和中性粒细胞积聚、免疫失调、细胞因子风暴、急性呼吸窘迫综合征（ARDS）等。由于疫苗在动物模型中诱导增强的疾病反应，因此很难开发针对严重急性呼吸综合征（SARS）、中东呼吸综合征冠状病毒（MERS-CoV）和其他冠状病毒的疫苗。包括 SARS-CoV-2 和 SARS-CoV-1 在内的多种 β 冠状病毒通过摄取病毒的抗体结合 Fc 受体来感染一些吞噬细胞（未成熟的巨噬细胞和树突状细胞），从而扩大细胞向性。抗体依赖性增强（ADE）可能参与患者早期高水平 SARS-CoV-2 抗体相关症状严重程度增加的临床观察。患有与 COVID-19 相关的儿童多系统炎症综合征 (MIS-C) 的婴儿也可能患有由母体获得的与肥大细胞结合的 SARS-CoV-2 抗体引起的 ADE。与 SARS-CoV-2 相关的 ADE 风险对 COVID-19 和 MIS-C 治疗、B 细胞疫苗、SARS-CoV-2 抗体治疗和患者恢复期血浆治疗产生影响。与肥大细胞结合的 SARS-CoV-2 抗体可能与初次感染 COVID-19 后的 MIS-C 和成人多系统炎症综合征 (MIS-A) 有关。与巨噬细胞和肥大细胞上的 Fc 受体结合的 SARS-CoV-2 抗体可能代表了患者 ADE 的两种不同机制。这两种不同的 ADE 风险可能对基于年龄、交叉反应抗体、抗体水平随时间变化和怀孕情况的人群子集的 SARS-CoV-2 B 细胞疫苗产生影响。这些模型越来越强调开发不依赖于抗体的安全 SARS-CoV-2 T 细胞疫苗的重要性。
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease progression include lymphopenia, elevated proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lungs, immune dysregulation, cytokine storms, acute respiratory distress syndrome (ARDS), etc. Development of vaccines to severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome coronavirus (MERS-CoV), and other coronavirus has been difficult to create due to vaccine induced enhanced disease responses in animal models. Multiple betacoronaviruses including SARS-CoV-2 and SARS-CoV-1 expand cellular tropism by infecting some phagocytic cells (immature macrophages and dendritic cells) via antibody bound Fc receptor uptake of virus. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of increased severity of symptoms associated with early high levels of SARS-CoV-2 antibodies in patients. Infants with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 may also have ADE caused by maternally acquired SARS-CoV-2 antibodies bound to mast cells. ADE risks associated with SARS-CoV-2 has implications for COVID-19 and MIS-C treatments, B-cell vaccines, SARS-CoV-2 antibody therapy, and convalescent plasma therapy for patients. SARS-CoV-2 antibodies bound to mast cells may be involved in MIS-C and multisystem inflammatory syndrome in adults (MIS-A) following initial COVID-19 infection. SARS-CoV-2 antibodies bound to Fc receptors on macrophages and mast cells may represent two different mechanisms for ADE in patients. These two different ADE risks have possible implications for SARS-CoV-2 B-cell vaccines for subsets of populations based on age, cross-reactive antibodies, variabilities in antibody levels over time, and pregnancy. These models place increased emphasis on the importance of developing safe SARS-CoV-2 T cell vaccines that are not dependent upon antibodies.
登录
查看更多内容
影响因子：
5.4
作者：
Gao, Jing;Lu, Guangwen;Gao, George F.
通讯作者：
Gao, George F.
影响因子：
9
作者：
Channappanavar R;Perlman S
通讯作者：
Perlman S
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
影响因子：
11.8
作者：
Guzman MG;Alvarez M;Rodriguez-Roche R;Bernardo L;Montes T;Vazquez S;Morier L;Alvarez A;Gould EA;Kouri G;Halstead SB
通讯作者：
Halstead SB
影响因子：
12.7
作者：
Huang, KJ;Su, IJ;Lei, HY
通讯作者：
Lei, HY